HOOKIPA Pharma Inc. (HOOK)
PNK · Healthcare · Biotechnology
Closing price as of 2026-07-17 · Source: TEK2day Finance
Key Metrics
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Quarterly Financials
| Metric | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 4.7M | 1.4M | 2.0M | 6.8M |
| Operating Income | (15.4M) | (16.7M) | (17.5M) | (6.5M) |
| Net Income | (13.8M) | (24.9M) | (15.4M) | (1.8M) |
| Diluted EPS | $-1.10 | N/A | $-1.23 | $-0.40 |
Annual Financials
| Metric | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 18.4M | 14.2M | 20.1M | 43.9M |
| Operating Income | (72.0M) | (65.2M) | (73.7M) | (37.4M) |
| Net Income | (75.7M) | (64.9M) | (81.6M) | (43.5M) |
| Diluted EPS | $-23.00 | $-9.90 | $-8.63 | $-3.47 |